Eli Lilly has been quietly running phase 1b trials combining Eloralintide (a selective amylin receptor agonist / SARA) with Tirzepatide — results just surfaced in the EASD 2026 conference abstracts. The combo produces bariatric-surgery-level weight loss, faster than anything seen in a drug trial.
📊 KEY RESULTS
| Regimen |
Wks |
Weight Loss |
| Placebo + TZP 5mg | 16 | -10.0% |
| Elora 3mg + TZP 5mg | 16 | -17.0% |
| Elora 9mg + TZP 5mg | 16 | -20.5% |
| Placebo + TZP 15mg | 32 | -17.8% |
| Elora 9mg + TZP 15mg | 32 | -29.0% 🔥 |
| Elora 9mg + TZP 15mg (Study B) | 24 | -25.5% 🔥 |
17% in 16 weeks with just 3mg Elora + 5mg Tirz — that's what 2.4mg semaglutide does in 72 weeks. The 29% arm matched retatrutide's best results in a fraction of the time. Eloralintide's SARA mechanism avoids calcitonin activity — likely why it doesn't carry CagriSema's side effect baggage.
Lilly's Enlighten-6 trial adds Eloralintide after you plateau on Tirz or Sema. Phase 2 in Type 2 diabetics wraps August 2026 — results expected at Obesity Week in November.
âš ï¸ Caveats: Phase 1b — small groups (3–16 patients), short duration, high dropout likely from rapid weight loss. Side effects mostly mild-to-moderate GI. Proof of concept only.
📖 READ FULL ARTICLE — THE INCRETINS ↗